ArticleACS omega2021
MXene-Graphene Field-Effect Transistor Sensing of Influenza Virus and SARS-CoV-2.
Article in ACS omega, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis.PLoS medicine · 2021Pooled it
- Tissue-adhesive hydrogel-MXene biosensor for in situ intraoral TNF-α detection.Science advances · 2026Article
- Two-Dimensional MXenes as Next-Generation Nanomaterials for Biosensing and Hydrogen Production.Nanotechnology, science and applications · 2026Review
- Advanced Materials for Biological Field-Effect Transistors (Bio-FETs) in Precision Healthcare and Biosensing.Advanced healthcare materials · 2025Review
- 3D porous structure of ionic liquid-delaminated TiScientific reports · 2025Article
- Ultraprecise Detection of Influenza Virus by Antibody-Modified Graphene Transistors.Sensors (Basel, Switzerland) · 2025Article
- Recent Advances in Field-Effect Transistor-Based Biosensors for Label-Free Detection of SARS-CoV-2.Small science · 2024Article
- Low-Cost Biosensor Technologies for Rapid Detection of COVID-19 and Future Pandemics.ACS nano · 2024Review
- Asymmetric Schottky Barrier-Generated MoSNanomaterials (Basel, Switzerland) · 2024Article
- Future prospects of MXenes: synthesis, functionalization, properties, and application in field effect transistors.Nanoscale advances · 2024Review
- Advances in nanobiosensors during the COVID-19 pandemic and future perspectives for the post-COVID era.Nano convergence · 2024Review
- Two-Dimensional (2D) materials in the detection of SARS-CoV-2.Microchemical journal : devoted to the application of microtechniques in all branches of science · 2023Article
- Review on two-dimensional material-based field-effect transistor biosensors: accomplishments, mechanisms, and perspectives.Journal of nanobiotechnology · 2023Review
- Electrochemical and Bioelectrochemical Sensing Platforms for Diagnostics of COVID-19.Biosensors · 2023Review
- Emerging Trends and Recent Progress of MXene as a Promising 2D Material for Point of Care (POC) Diagnostics.Diagnostics (Basel, Switzerland) · 2023Review
- Electrical biosensing system utilizing ion-producing enzymes conjugated with aptamers for the sensing of severe acute respiratory syndrome coronavirus 2.Sensing and Bio-Sensing Research · 2023Article
- Towards hospital-on-chip supported by 2D MXenes-based 5Biosensors & bioelectronics · 2023Review
- Recent advances of nanotechnology in COVID 19: A critical review and future perspective.OpenNano · 2023Review
- Latest advances on MXenes in biomedical research and health care.MRS bulletin · 2023Review
- Nucleotide detection mechanism and comparison based on low-dimensional materials: A review.Frontiers in bioengineering and biotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An MXene-graphene field-effect transistor (FET) sensor for both influenza virus and 2019-nCoV sensing was developed and characterized. The developed sensor combines the high chemical sensitivity of MXene and the continuity of large-area high-quality graphene to form an ultra-sensitive virus-sensing transduction material (VSTM). Through polymer linking, we are able to utilize antibody-antigen binding to achieve electrochemical signal transduction when viruses are deposited onto the VSTM surface. The MXene-graphene VSTM was integrated into a microfluidic channel that can directly receive viruses in solution. The developed sensor was tested with various concentrations of antigens from two viruses: inactivated influenza A (H1N1) HA virus ranging from 125 to 250,000 copies/mL and a recombinant 2019-nCoV spike protein ranging from 1 fg/mL to 10 pg/mL. The average response time was about ∼50 ms, which is significantly faster than the existing real-time reverse transcription-polymerase chain reaction method (>3 h). The low limit of detection (125 copies/mL for the influenza virus and 1 fg/mL for the recombinant 2019-nCoV spike protein) has demonstrated the sensitivity of the MXene-graphene VSTM on the FET platform to virus sensing. Especially, the high signal-to-viral load ratio (∼10% change in source-drain current and gate voltage) also demonstrates the ultra-sensitivity of the developed MXene-graphene FET sensor. In addition, the specificity of the sensor was also demonstrated by depositing the inactivated influenza A (H1N1) HA virus and the recombinant 2019-nCoV spike protein onto microfluidic channels with opposite antibodies, producing signal differences that are about 10 times lower. Thus, we have successfully fabricated a relatively low-cost, ultrasensitive, fast-responding, and specific inactivated influenza A (H1N1) and 2019-nCoV sensor with the MXene-graphene VSTM.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.